To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had ...

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her ...

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young ...

James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of ...

As ophthalmic technology continues to advance, new diagnostic and surgical devices are redefining precision, efficiency, and ...

The Phase 2 OptimUM-09 trial shows promising results for uveal melanoma, addressing the lack of approved systemic therapies.

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient ...

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...